Last updated on April 2016

Phase I Study of BAY1436032 in Isocitrate Dehydrogenase-1 (IDH1)-Mutant Advanced Solid Tumors


Brief description of study

In patients with IDH1-R132X-mutant solid tumors treated with BAY1436032: 1. Determine the safety, tolerability, maximum tolerated dose (MTD) or recommended phase II dose (RP2D) of BAY1436032; 2. Evaluate the pharmacokinetic (PK) properties and pharmacodynamic (PD) effects of BAY1436032; 3. Look for preliminary evidence of clinical efficacy in patients treated with BAY1436032; 4. Evaluate effect of standard high-fat, high calorie meal on the PK of BAY1436032.

Clinical Study Identifier: NCT02746081

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.